کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9093622 | 1149524 | 2005 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Cetuximab in Previously Treated Colorectal Cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیهوشی و پزشکی درد
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Cetuximab in Previously Treated Colorectal Cancer Cetuximab in Previously Treated Colorectal Cancer](/preview/png/9093622.png)
چکیده انگلیسی
Within the past decade, there have been considerable advances in the first- and second-line treatment of colorectal cancer (CRC). For many years, 5-fluorouracil was the only therapeutic option for the first-line treatment of CRC, and virtually no effective salvage therapies were available. However, the advent of oxaliplatin and irinotecan has improved outcomes for advanced CRC, providing increased therapeutic choice in the first-line setting and effective salvage therapies. Many patients are now receiving multiple lines of therapy, and it is in the setting of previously treated CRC that cetuximab, a monoclonal antibody to the epidermal growth factor receptor, has been successfully developed based on sound scientific principles. The ability to integrate new biologic therapies with conventional cytotoxic agents marks a new treatment era for this disease. This review discusses the development of cetuximab in pretreated CRC to date and future directions with this novel therapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Colorectal Cancer - Volume 5, Supplement 1, April 2005, Pages S28-S33
Journal: Clinical Colorectal Cancer - Volume 5, Supplement 1, April 2005, Pages S28-S33
نویسندگان
Naureen Starling, David Cunningham,